LASA Latest Share Price (LASA)
TODAY IN ONE LINE
With a market cap of ₹32.82 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
LASA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.20x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Promoter SellingPromoter holding decreased by 53.65% QoQ
Latest LASA News
What changed recently?
Recent events, corporate actions, and announcements.
LASA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for LASA, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
LASA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for LASA — derived from the latest tape, not yesterday's close.
LASA last traded at ₹6.52 with an intraday range of ₹6.45–₹6.71 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹6.52| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 7.19 | +0.67 | +10.28% |
| R3 | 6.93 | +0.41 | +6.29% |
| R2 | 6.82 | +0.30 | +4.60% |
| R1 | 6.67 | +0.15 | +2.30% |
| PIVOT | 6.56 | 0.04 | 0.61% |
| CURRENT | 6.52 | — | — |
| S1 | 6.41 | -0.11 | -1.69% |
| S2 | 6.30 | -0.22 | -3.37% |
| S3 | 6.15 | -0.37 | -5.67% |
| S4 | 5.89 | -0.63 | -9.66% |
LASA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Below opening range, showing Bearishness
LASA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for LASA — consolidated or standalone — with margins, YoY growth and key ratios inline.
LASA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹32.82 Cr. and reported EPS of ₹-0.71.
LASA segment analysis : revenue and profit mix.
Disclosed business segments at LASA with their share of revenue and profit, switchable between consolidated and standalone reporting.
LASA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for LASA.
Our AI distills the core fundamental drivers supporting LASA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
LASA's investment case rests on 10 positive markers and 14 flagged concerns drawn from the latest reported filings.
What you're getting.
Stable promoter holding of 43.78% ensures management commitment and operational control
Conservative debt-to-equity ratio of 0.0020 indicates minimal financial leverage and prudent capital structure
Price-to-book ratio of 0.75 suggests potential undervaluation relative to tangible book value
Niche API portfolio spanning human and animal health provides diversified revenue exposure
Export-focused business model taps international pharmaceutical and veterinary markets globally
Key Risks.
Operating margin of -136.12% reflects catastrophic profitability collapse and operational distress
Net profit margin of -135.60% indicates severe losses; company losing ₹1.36 per rupee of sales
Return on equity of -68.70% and ROCE of -57.92% destroying shareholder capital systematically
Latest quarterly sales of ₹1.23 Cr show severe demand contraction and revenue collapse
Operating cash flow negative ₹22.83 Cr signals unsustainable cash burn and acute liquidity stress
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
LASA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — LASA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
LASA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for LASA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
LASA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for LASA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in LASA stood at 88.6% of traded volume, against a 20-day average of 74.6%.
LASA announcements: results, concalls, ratings, M&A.
Filings LASA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
LASA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 58 documents below.
General Updates
Lasa Supergenerics Limited has informed the Exchange about General Updates
Outcome of Board Meeting
Lasa Supergenerics Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026.
Clarification - Financial Results
The Exchange has sought clarification from Lasa Supergenerics Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI…
Outcome of Board Meeting
Appointment of Mr Janardan Savala as additonal director in capacity of Executive Director
Cessation
Lasa Supergenerics Limited has informed the Exchange regarding Cessation of Mr. ganesh as Executive Director of the company w.e.f. August 25, 2026.
LASA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue LASA has declared, sequenced by announce and record date.
LASA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About LASA: business, sector, key facts.
What LASA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
LASA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: LASA, BSE: 540702.
Lasa Supergenerics Limited is an Indian company established in 2016 that operates within the healthcare sector, focusing on both human and animal health products. Their core business revolves around the research, manufacturing, and marketing of these products, encompassing a broad spectrum of activities within the pharmaceutical and veterinary industries.
A significant portion of Lasa's business centers on the production and sale of Active Pharmaceutical Ingredients (APIs). These APIs form the foundational components of many medications and are crucial for the manufacturing of both human and animal drugs. Their API portfolio is diverse, including key substances such as fenbendazole, albendazole, closantel, and various other compounds used in treating parasitic infections and other health conditions in animals. They also produce APIs for human use, illustrating their reach across both sectors.
Beyond APIs, Lasa Supergenerics Limited manufactures and supplies animal feed ingredients. This expands their role in the animal health market, offering essential components for complete animal nutrition solutions. The inclusion of calcium iodate as a notable product highlights their commitment to providing crucial nutritional supplements for livestock.
Furthermore, the company produces and provides reagents for therapeutic applications. These reagents, such as potassium iodide, are important components used in various medical and veterinary treatments. This further diversifies their product offerings and strengthens their position within the healthcare sector.
Finally, a key aspect of Lasa's business model involves exporting its products. This international reach demonstrates their capacity to compete on a global scale and indicates a significant contribution to the international pharmaceutical and veterinary supplies market. Their operations encompass the entire chain, from research and development to manufacturing, marketing, and distribution both domestically and internationally.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about LASA (LASA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of LASA (LASA)?
The current share price of LASA (LASA) is ₹6.52. Today, the stock has declined by ₹0.17 (2.54%), trading in a range of ₹6.45 to ₹6.71. The stock opened at ₹6.71 with a trading volume of 46,913 shares.
02What is the 52-week high and low price of LASA stock?
The 52-week high price of LASA (LASA) is ₹14.08, while the 52-week low is ₹5.67. Currently trading at ₹6.52, the stock is 14.99% above its 52-week low and 53.69% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of LASA and when is the next dividend?
LASA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹6.52, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is LASA stock performing today in the market?
LASA stock opened at ₹6.71 and is currently trading at ₹6.52, showing a decline of ₹0.17 (2.54%). The intraday high is ₹6.71 and low is ₹6.45. The trading volume stands at 46,913 shares, indicating moderate market participation today.
05What is the market capitalization of LASA?
LASA has a market capitalization of ₹32.82 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹6.52) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of LASA?
LASA has a Return on Equity (ROE) of -68.7% and Return on Capital Employed (ROCE) of -57.92%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does LASA belong to?
LASA operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of LASA?
LASA has a debt-to-equity ratio of 0.2, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about LASA (LASA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.